top of page
AI pixabay huge.jpg

Digital Biomarkers As Endpoints In Parkinson's Disease

The Unified Parkinson’s Disease Rating Scale (UPDRS) is the gold standard for diagnosing and staging PD and is a standard primary endpoint in clinical trials to evaluate therapeutic efficacy of novel drugs and interventions. However, the UPDRS is an imperfect stand-alone tool as its scoring can be time consuming, subjective, and episodic. There is, therefore, a critical need for developing and validating biomarkers in conjunction with the UPDRS to generate objective, quantitative metrics of disease probability, severity, and risk for progression. These biomarkers hold potential for screening patients and assessing therapeutic efficiency during clinical trials



Commentaires


bottom of page